Rapid propagation of low-fitness drug-resistant mutants of human immunodeficiency virus type 1 by a streptococcal metabolite sparsomycin

Antiviral Chemistry and Chemotherapy

Volumn 17, Issue 4, 2006, Pages 167-174

  Miyauchi, Kosuke ^a   Komano, Jun ^a   Myint, Lay ^a   Futahashi, Yuko ^a   Urano, Emiko ^a   Matsuda, Zene ^a   Chiba, Tomoko ^a   Miura, Hideka ^a   Sugiura, Wataru ^a   Yamamoto, Naoki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Drug resistant mutants; Enhancement of replication; HIV 1; Low fitness mutants; Sparsomycin

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; SPARSOMYCIN; STAVUDINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS MUTANT; VIRUS REPLICATION; BIOLOGICAL MODEL; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; IC 50; METABOLISM; MUTATION; STREPTOCOCCACEAE;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; MUTATION; SPARSOMYCIN; STREPTOCOCCACEAE; TRANSFECTION; VIRUS REPLICATION;

EID: 33947151484     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020601700401     Document Type: Article

References (31)

1. Ash RJ, Fite LD, Beight DW & Flynn GA (1984) Importance of the hydrophobic suifoxide substituent on nontoxic analogs of sparsomycin. Antimicrobial Agents and Chemotherapy 25:443-445.
2. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N & Markowitz M (1999) HIV-1 drug resistance in newly infected individuals. Journal of the American Medical Association 282:1135-1141.
3. Devereux HL, Emery VC, Johnson MA & Loveday C (2001) Replicative fitness in vivo of HIV-1 variants with multiple drug resistance- associated mutations. Journal of Medical Virology 65:218-224.
4. Dinman JD, Ruiz-Echevarria MJ, Czaplinski K & Peltz SW (1997) Peptidyl-transferase inhibitors have antiviral properties by altering programmed -1 ribosomal frameshifting efficiencies: development of model systems. Proceedings of the National Academy of Sciences of the United States of America 94:6606-6611.
5. Dulude D, Baril M & Brakier-Gingras L (2002) Characterization of the frameshift stimulatory signal controlling a programmed -1 ribosomal frameshift in the human immunodeficiency virus type 1. Nucleic Acids Research 30:5094-5102.
6. Gehringer H, Bogner JR, Goebel FD, Nitschko H & von der Helm K (2000) Sequence analysis of the HIV-1 protease coding region of 18 HIV-1-infected patients prior to HAART and possible implications on HAART. Journal of Clinical Virology 17:137-141.
7. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B & Pauwels R (1998) A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrobial Agents and Chemotherapy 42:269-276.
8. Hirsch, MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson, VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM & Richman DD (2000) Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. Journal of the American Medical Association 283:2417-2426.
9. Hung M, Patel P, Davis S & Green SR (1998) Importance of ribosomal frameshifting for human immunodeficiency virus type 1 particle assembly and replication. Journal of Virology 72:4819-4824.
10. Iga M, Matsuda Z, Okayama A, Sugiura W, Hashida S, Morishita K, Nagai Y & Tsubouchi H (2002) Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. Journal of Virological Methods 106:25-37.
11. Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ & Varmus HE. (1988) Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331:280-283.
12. Jarmy G, Heinkelein M, Weissbrich B, Jassoy C & Rethwilm A (2001) Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system. Journal of Medical Virology 64:223-231.
13. Kantor R, Fessel WJ, Zolopa AR, Israelski D, Shulman N, Montoya JG, Harbour M, Schapiro JM & Shafer RW (2002) Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrobial Agents and Chemotherapy 46:1086-1092.
14. Kellam P & Larder BA (1994) Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrobial Agents and Chemotherapy 38:23-30.
15. Komano J, Miyauchi K, Matsuda Z & Yamamoto N (2004). Inhibiting the Arp2/3 Complex limits infection of both intracellular mature vaccinia virus and primate lentiviruses. Mol Biol Cell 15:5197-5207.
16. Levin JG, Hatfield DL, Oroszlan S & Rein A (1993) Mechanisms of translational suppression used in the biosynthesis of reverse transcriptase. In Reverse transcriptase, pp. 5-31. Edited by AM Skalka & SP Goff. New York: Cold Spring Harbor Laboratory Press.
17. Matsuda Z, Yu X, Yu QC, Lee TH & Essex M (1993) A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America 90:3544-3548.
18. Menzo S, Rusconi S, Monachetti A, Colombo MC, Violin M, Bagnarelli P, Varaldo PE, Moroni M, Galli M, Balotta C & Clementi M (2000) Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy. AIDS 14:1101-1110.
19. Miyauchi K, Komano J, Yokomaku Y, Sugiura W, Yamamoto N & Matsuda, Z (2005) Role of the specific amino acid sequence of the membrane-spanning domain of human immunodeficiency virus type 1 in membrane fusion. Journal of Virology 79:4720-4729.
20. Nakajima N, Enomoto T, Watanabe T, Matsuura N & Ubukata M. (2003) Synthesis and activity of pyrimidinylpropenamide antibiotics: the alkyl analogues of sparsomycin. Bioscience, Biotechnology, and Biochemistry 67:2556-2566.
21. Ottenheijm HC, van den Broek LA, Ballesta JP & Zylicz Z (1986) Chemical and biological aspects of sparsomycin, an antibiotic from Streptomyces. Progress in Medicinal Chemistry 23:219-268.
22. Parkin NT, Chappey C & Petropoulos CJ (2003) Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 17:955-961.
23. Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ & Pellegrin JL (2002) Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 16:1331-1340.
24. Porse BT, Kirillov SV, Awayez MJ, Ottenheijm HC & Garrett RA (1999) Direct crosslinking of the antitumor antibiotic sparsomycin, and its derivatives, to A2602 in the peptidyl transferase center of 23S-like rRNA within ribosome-tRNA complexes. Proceedings of the National Academy of Sciences of the United States of America 96:9003-9008.
25. Rodriguez-Rosado R, Briones C & Soriano V (1999) Introduction of HIV drug-resistance testing in clinical practice. AIDS 13:1007-1014.
26. Sarmati L, Nicastri E, Parisi SG, d'Ettorre G, Mancino G, Narciso P, Vullo V & Andreoni M (2002) Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells. Journal of Clinical Microbiology 40:335-340.
27. Shehu-Xhilaga M, Crowe SM & Mak J (2001) Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity. Journal of Virology 75:1834-1841.
28. Sugiura W, Matsuda Z, Yokomaku Y, Hertogs K, Larder B, Oishi T, Okano A, Shiino T, Tatsumi M, Matsuda M, Abumi H, Takata N, Shirahata S, Yamada K, Yoshikura H & Nagai Y (2002) Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type I. Antimicrobial Agents and Chemotherapy 46:708-715.
29. Walter H, Schmidt B, Korn K, Vandamme AM, Harrer T & Uberla K. (1999). Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. Journal of Clinical Virology 13:71-80.
30. Xie D, Gulnik S, Gustchina E, Yu B, Shao W, Qoronfleh W, Nathan A & Erickson JW (1999) Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH. Protein Science 8:1702-1707.
31. Yerly S, Kaiser L, Race E, Bru JP, Clavel F & Perrin L (1999) Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354:729-733.